DPP-4抑制剂治疗2型糖尿病合并非酒精性脂肪肝的作用研究进展  

Progress of research on the mechanism of DPP-4 inhibitors in the treatment of type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease

作　　者：张晓 张瑞 王慧 王渊 徐静 ZHANG Xiao;ZHANG Rui;WANG Hui;WANG Yuan;XU Jing(Department of Endocrinology,the Second Affiliated Hospital of Army Medical University,Chongqing,China,400037)

机构地区：[1]陆军军医大学第二附属医院内分泌科,重庆400037

出　　处：《分子诊断与治疗杂志》2024年第1期1-4,9,共5页Journal of Molecular Diagnostics and Therapy

基　　金：重庆市科卫联合医学科研项目(2020MSXM085)。

摘　　要：二肽基肽酶4(DPP-4)抑制剂是一种较新类型的糖尿病治疗药物,其主要的降糖机制是通过减少肠促胰素降低,来提高内源性胰高血糖素样肽1,进而促进胰岛素分泌与抑制胰高血糖素分泌,降低机体血糖水平。2型糖尿病(T2DM)与非酒精性脂肪肝(NAFLD)是临床常见的疾病类型,发病率居高不下。T2DM和NAFLD能够相互影响,相互促进,T2DM合并NAFLD不仅容易提高心血管疾病的患病风险与加重内分泌代谢紊乱,而且容易推动NAFLD病情进展,导致出现肝硬化、肝癌等恶性病变。目前大量研究显示,DPP-4抑制剂能够有效降低T2DM患者血糖水平和改善胰岛素抵抗,且对NAFLD具有较好的预防作用。本文从DPP-4抑制剂对治疗T2DM合并NAFLD的疗效与安全性方面进行综述。Dipeptidyl peptidase 4(DPP-4)inhibitor is a new type of diabetes therapy drug.The main hypoglycemic mechanism of dipeptidyl peptidase 4 inhibitor is to increase endogenous glucagon-like peptide 1 by reducing the reduction of enterocagon,thus promoting insulin secretion and inhibiting glucagon secretion,and reducing blood glucose level in the body.Type 2 diabetes mellitus(T2DM)and non-alcoholic fatty liver disease(NAFLD)are common types of diseases in clinical,and the incidence is high.T2DM and NAFLD can influence and promote each other.T2DM combined with NAFLD not only tends to increase the risk of cardiovascular diseases and aggravate endocrine and metabolic disorders,but also tends to promote the progression of NAFLD,leading to liver cirrhosis,liver cancer and other malignant lesions.Many studies have shown that DPP-4 inhibitors can effectively reduce blood glucose levels and improve insulin resistance in patients with T2DM and have a good preventive effect on NAFLD.This article reviews the efficacy and safety of DPP-4 inhibitors in the treatment of T2DM with NAFLD.

关 键 词：二肽基肽酶4抑制剂 2型糖尿病 非酒精性脂肪肝 

分 类 号：R587.2[医药卫生—内分泌] R575.5[医药卫生—内科学]